KRAS and non-small cell lung carcinoma: The identification of comutations in KRAS and TP53 has been related to higher levels of radioresistance in in vitro and in vivo models based on cell lines and xenografts of NSCLC, proposing the escalation of radiotherapeutic dose and/or radiosensitization by tyrosine kinase inhibitors as routes to overcome this resistance [75]